Press Release

July 22, 2021

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Press Release

July 22, 2021

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Press Release

July 22, 2021

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Press Release

July 22, 2021

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Press Release

July 1, 2021

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Press Release

July 1, 2021

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Press Release

July 1, 2021

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Press Release

July 1, 2021

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Press Release

June 15, 2021

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Press Release

June 15, 2021

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Press Release

June 15, 2021

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Press Release

June 15, 2021

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Press Release

December 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Press Release

December 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Press Release

December 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Press Release

December 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Press Release

October 1, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Press Release

October 1, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Press Release

October 1, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Press Release

October 1, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Press Release

January 21, 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Press Release

January 21, 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Press Release

January 21, 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Press Release

January 21, 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Press Release

November 6, 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Press Release

November 6, 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Press Release

November 6, 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Press Release

November 6, 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Press Release

November 5, 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Press Release

November 5, 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Press Release

November 5, 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Press Release

November 5, 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Press Release

August 21, 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Press Release

August 21, 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Press Release

August 21, 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Press Release

August 21, 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Press Release

June 14, 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Press Release

June 14, 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Press Release

June 14, 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Press Release

June 14, 2018

Press Release

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Navigation

Contact Us